EA201990513A1 - АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ - Google Patents

АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ

Info

Publication number
EA201990513A1
EA201990513A1 EA201990513A EA201990513A EA201990513A1 EA 201990513 A1 EA201990513 A1 EA 201990513A1 EA 201990513 A EA201990513 A EA 201990513A EA 201990513 A EA201990513 A EA 201990513A EA 201990513 A1 EA201990513 A1 EA 201990513A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
bone diseases
pparγ agonist
pparγ
agonist
Prior art date
Application number
EA201990513A
Other languages
English (en)
Russian (ru)
Inventor
Деннис Ланфир
Original Assignee
Интекрин Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интекрин Терапьютикс, Инк. filed Critical Интекрин Терапьютикс, Инк.
Publication of EA201990513A1 publication Critical patent/EA201990513A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
EA201990513A 2016-08-18 2017-08-18 АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ EA201990513A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Publications (1)

Publication Number Publication Date
EA201990513A1 true EA201990513A1 (ru) 2019-08-30

Family

ID=61197122

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990513A EA201990513A1 (ru) 2016-08-18 2017-08-18 АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ

Country Status (11)

Country Link
US (1) US20190167660A1 (https=)
EP (1) EP3500269A4 (https=)
JP (2) JP2019524889A (https=)
KR (1) KR20190065252A (https=)
CN (1) CN109843292A (https=)
AU (1) AU2017313842A1 (https=)
BR (1) BR112019003133A2 (https=)
CA (1) CA3033971A1 (https=)
EA (1) EA201990513A1 (https=)
SG (2) SG10202101500WA (https=)
WO (1) WO2018035449A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
ES2785317T3 (es) * 2014-10-10 2020-10-06 Liminal Biosciences Ltd Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis

Also Published As

Publication number Publication date
KR20190065252A (ko) 2019-06-11
EP3500269A4 (en) 2020-04-15
SG10202101500WA (en) 2021-03-30
SG11201901328VA (en) 2019-03-28
US20190167660A1 (en) 2019-06-06
WO2018035449A1 (en) 2018-02-22
BR112019003133A2 (pt) 2019-05-21
AU2017313842A1 (en) 2019-03-07
JP2022116294A (ja) 2022-08-09
CA3033971A1 (en) 2018-02-22
JP2019524889A (ja) 2019-09-05
CN109843292A (zh) 2019-06-04
EP3500269A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
CU20210029A7 (es) Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
MX373154B (es) Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX380092B (es) Tratamiento de la osteoartritis.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
EA201691135A1 (ru) Новые ингибиторы глутаминазы
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201591382A1 (ru) Ингибиторы гистондеметилаз
MX379920B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
EA201791095A1 (ru) Способ лечения рака
EA201692480A1 (ru) Фармацевтическая композиция
EA201890567A1 (ru) Способ лечения рака
MX391040B (es) Formulacion de alta concentracion.
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
BR112017006420A2 (pt) derivados de ácido borônico
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину